Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

61.17 +1.55 (+2.60%)

Delayed Quote Updated: 3:59 PM EDT, Oct 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

38 39 Next >

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 89bio, Inc. (Nasdaq - ETNB), Barinthus Biotherapeutics plc (Nasdaq - BRNS), Verint Systems Inc. (Nasdaq - VRNT), Dayforce, Inc. (NYSE- DAY)

October 08, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

FDA Greenlights Jazz and Roche's Zepzelca-Tecentriq for ES-SCLC Maintenance, Reshaping Lung Cancer Treatment Landscape

October 03, 2025

In a pivotal moment for oncology, the U.S. Food and Drug Administration (FDA) on October 2, 2025, granted approval for the innovative combination of Jazz Pharmaceuticals' (NASDAQ: JAZZ) Zepzelca...

Via MarketMinute

89bio Stock Skyrockets After Roche’s $3.5B Buyout Offer: Retail Bullish, But A Wall Street Analyst Is Cautious ↗

September 18, 2025

Via Stocktwits

Why Did 89bio Stock Nearly Double In Value Today? ↗

September 18, 2025

Via Stocktwits

Big Pharma Eyes China: J&J And Roche Reportedly In Talks For Henlius’ Experimental Cancer Drug ↗

September 15, 2025

Via Stocktwits

Novartis Rides Bullish Retail Mood, Roche Faces Gloom Amid Swiss-US Trade Concerns ↗

August 11, 2025

Via Stocktwits

FDA Approves Genentech’s Tecentriq Plus Lurbinectedin as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

October 02, 2025

From Genentech

Via Business Wire

Generative AI Unleashes a New Era in Genome Editing, Outperforming Nature in Protein Design

October 02, 2025

London, UK – October 2, 2025 – In a monumental stride for biotechnology and medicine, generative artificial intelligence (AI) has achieved a scientific breakthrough, demonstrating an unprecedented...

Via TokenRing AI

Topics Artificial Intelligence

GSK Leaps Into Buy Zone On Surprise Departure Of CEO Emma Walmsley ↗

September 29, 2025

Shares had broke out earlier this month, but have floundered at the lower boundary of the chart pattern.

Via Investor's Business Daily

Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet ↗

September 26, 2025

Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de

Via Benzinga

Topics Government World Trade

Prediction: 2 Stocks That Will Be Worth More Than BigBear.ai 5 Years From Now ↗

September 26, 2025

BigBear.ai is bigger than both of these AI-focused companies now. That could change.

Via The Motley Fool

Topics Artificial Intelligence

Trump Shocks Pharma With 100% Tariff On Imported Drugs Unless Companies Build In America ↗

September 25, 2025

Via Stocktwits

Topics Government

Eli Lilly Ends Bimagrumab Obesity Study Weeks After Launch ↗

September 25, 2025

On Wednesday, Eli Lilly & Co. (NYSE: LLY) ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began.

Via Benzinga

Genentech Presents New Data for Ocrevus and Fenebrutinib Across Broad Patient Populations at ECTRIMS 2025

September 24, 2025

From Genentech

Via Business Wire

Viking Therapeutics Stock Gets Boost From Pfizer-Metsera Deal, Says BTIG — Retail Slams Rivals For Buying ‘Inferior Pipelines’ ↗

September 22, 2025

BTIG said Pfizer’s $7.3 billion Metsera acquisition sharpens its clinical updates and strategic optionality.

Via Stocktwits

Big Pharma's Epicenter Shift: Eli Lilly and the Reshaping of the Weight-Loss Drug Market

September 22, 2025

The pharmaceutical industry is currently witnessing a transformative battle for dominance in the burgeoning weight-loss drug market, with Eli Lilly (NYSE: LLY) firmly at the forefront. What was once a...

Via MarketMinute

Topics Economy Intellectual Property

Roche Targets Top Spot In Weight Loss Drug Market ↗

September 22, 2025

Roche advances weight loss drug CT-388 to Phase III, boosts pipeline with major acquisitions.

Via Benzinga

Positive Phase III Results Show Genentech’s Giredestrant Significantly Improved Progression-Free Survival in ER-positive Advanced Breast Cancer

September 22, 2025

From Genentech

Via Business Wire

The Pharmaceutical Revolution: AI, Gene Therapies, and Obesity Drugs Reshape a Trillion-Dollar Market

September 19, 2025

The global pharmaceutical sector stands at the precipice of a monumental transformation, driven by an unprecedented convergence of scientific breakthroughs, technological innovation, and evolving...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

The Healthcare Horizon: Navigating Innovation, Policy Shifts, and Evolving Patient Care

September 19, 2025

The global healthcare industry is currently in the midst of a profound metamorphosis, characterized by a rapid influx of technological innovation, significant shifts in policy, and evolving patient...

Via MarketMinute

Topics Artificial Intelligence

Deal Dispatch: Need M&A Approval? FCC Chair Explains How To Get It ↗

September 19, 2025

The "Jimmy Kimmel Live" drama coincided with reports of tit-for-tat maneuvering between the FCC and corporations desperate for deal approval.

Via Benzinga

Roche To Acquire 89bio For $2.4 Billion In Liver And Cardiometabolic Push ↗

September 18, 2025

Roche is acquiring 89bio for $2.4 billion plus potential milestone payouts, bolstering its pipeline with late-stage MASH drug pegozafermin.

Via Benzinga

Roche Digs Into Obesity-Tied Diseases With $3.5 Billion 89bio Buyout ↗

September 18, 2025

The company is now focusing on MASH, a form of fatty liver disease common in people with obesity and type 2 diabetes.

Via Investor's Business Daily

1 Super Stock Down More Than 20% to Buy Hand Over Fist, According to Wall Street ↗

September 12, 2025

The positives for this big drugmaker appear to outweigh the negatives.

Via The Motley Fool

Topics Earnings Government World Trade

BioNTech Surges 10% On Promising Test Results For Its Cancer Smart Bomb ↗

September 05, 2025

The company's DualityBio-partnered drug met the pre-specified bar for success in a pivotal study.

Via Investor's Business Daily

BioNTech Advances On Positive Phase 3 Breast Cancer Drug Data ↗

September 05, 2025

BioNTech and DualityBio reported Phase 3 success for trastuzumab pamirtecan in HER2 breast cancer, setting stage for regulatory submission in China.

Via Benzinga

2 High-Yield Dividend ETFs You Can Buy With $200 in September and Hold Forever ↗

September 05, 2025

You don't need to be rich to begin building a passive income stream that could fuel your retirement dreams.

Via The Motley Fool

Topics ETFs Retirement Stocks

New Data for Genentech’s Vabysmo Reinforce Its Efficacy, Safety and Durability in Wet Age-Related Macular Degeneration (AMD)

September 05, 2025

From Genentech

Via Business Wire

Genentech and Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial for People With Uncontrolled Hypertension

August 30, 2025

From Genentech

Via Business Wire

Genentech and Roche Break Ground on State-of-the-Art Manufacturing Facility in Holly Springs, North Carolina

August 25, 2025

From Genentech

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

38 39 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.